Press Release Hub logo
  • Submit a Release
  • Home
  • All
  • ESG
  • Health
  • Technology
  • Finance
  • Contributors

First Doses of BRUKINSA® provided to Patients with Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries Under Collaboration of The Max Foundation, BeiGene, and the BeiGene Foundation

Contributed by: Business Wire

Logo

Business Wire logo

Tags

Oncology
Philanthropy
Health
Foundation
Pharmaceutical
Cardiology
Biotechnology
The Max Foundation

More Like This

Business Wire logo

BeiGene Advances Leadership in CLL at ASH 2024 with New Data From Its Hematology Franchise Including BRUKINSA® and Novel Pipeline Assets

Business Wire logo

BeiGene to Present New Data from SEQUOIA Study Evaluating BRUKINSA® plus Venetoclax in High-Risk First-Line CLL/SLL at EHA2024

Business Wire logo

BeiGene Highlights Innovative Hematology Portfolio Across B-cell Malignancies at ASH 2024

Business Wire logo

BeiGene Highlights New Hematology Portfolio and Pipeline Data at EHA2024

Business Wire logo

Global Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual Meeting

Business Wire logo

BeiGene Highlights Waldenström’s Macroglobulinemia Innovation at IWWM 2024

Business Wire logo

BeiGene Announces First Quarter 2025 Financial Results and Business Updates

Business Wire logo

BeiGene Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates

Pages

  • Home
  • All
  • ESG
  • Health
  • Technology
  • Finance
  • Contributors

Press Release Hub

  • Our Services
  • Submit a Release

Websites

  • PA Media Group
  • PA Mediapoint
  • Distribution Packages

© PA Media Group. 2025

Terms of Use

Privacy Policy

Contact Us